

Title of	Governing Body Meeting		Agenda Item: 9.3
Meeting:			
Date of	24 June 2021		
Meeting:			Session (Tick)
Paper Title:	Quality and Clinical Governance Committee Key Public X		Public X
	Messages		Private
			Workshop
Responsible Governing Body Member Lead		Report Author and	Job Title
Kate Kennady, Lay Member for PPE and Chair		Kate Kennady, Lay Member for PPE and	
of the Quality 8	Clinical Governance Committee	Chair of the Quality	& Clinical Governance

Committee

Purpose				
(this paper				
if for)				

Decision	Discussion	Assurance	Information
		X	

Has the report (or variation of it) been presented to another Committee / Meeting? If yes, state the Committee / Meeting: No.

Executive Summary

The Quality and Clinical Governance Committee has been established to provide oversight on any quality or equality impact relating to all commissioned services through its review and monitoring of quality surveillance metrics that may indicate an adverse impact on quality or safety and therefore require further mitigation to be considered.

The Committee provides assurance to the Governing Body that any risk to equality and quality has been appropriately mitigated and how continuous improvement will be monitored. The Committee also monitors safeguarding and overseas the development of and approve policies relating to HR and Corporate.

The following assurance report details key topics discussed at recent meetings.

Recommendations

The Governing Body is asked to receive the report as assurance.

Monitoring

An assurance report on key topics discussed at the Quality and Clinical Governance Committee will be brought to each Governing Body meeting.

Any statutory / regulatory / legal / NHS Constitution implications	The Quality and Clinical Governance Committee is accountable to the Governing Body and is required to provide key messages from its meetings.	
Management of Conflicts of Interest	No conflicts of interest have been identified prior to the meeting.	
Communication / Public & Patient Engagement	Key Messages are published with the Governing Body Papers.	
Financial / resource implications	None identified.	
Significant Risks to Consider	No significant risks to consider.	
Outcome of Impact Assessments completed	Not applicable.	

Kate Kennady, Lay Member for Patient and Public Engagement and Chair of the Quality and Clinical Governance Committee

Quality and Clinical Governance Committee Key Messages

The Committee met virtually on Thursday, 2 June 2021 using Microsoft Teams. The committee was quorate, and there were no declarations of interest in relation to the business of the meeting.

Items approved:

- The Minutes from the 1 April 2021 were approved as a true and accurate record of the meeting.
- Quality/Equality Impact Assessments

Section 2:

- Functional Electrical Stimulation (FES)
- o Hernia
- Occuplastic Eye Problems
- o Refractive Error
- Minor Foot Problems
- Knee Arthroscopy
- Hip Arthroscopy

Section 3:

- o Pinguecula
- o Pterygium
- Various skin conditions
- o Allergy, Sleep Apnoea, Atopic Eczema in Children, Psorasis, Urticaria
- Domestic Abuse Policy

All other agenda items were noted and received assurance as listed below:

- QCGC Terms of Reference (TORs) to be considered at the June meeting of the NYCCG Governing Body
- CHC Choice Policy to be considered at the June meeting of the NYCCG Governing Body
- Serious Incidents, Incidents and Concerns Policy
- Patient Relations (PALs) Update
- Annual Quality Report
- Receipt of Internal Audit Reports
- Significant Risk Review
- COVID-19 Update
- Quality, Patient Safety and Performance Update by Exception
- Adult CHC Report & EOL/Fast Track
- Wheelchair Service
- SI Report Q4
- Children's Services and Children's Continuing Healthcare Report
- Modern Slavery and Human Trafficking statement
- 0-19 Consultation
- BP@home pathway
- Mental Health incl TCP Update Report
- LeDER Report
- Safeguarding Children Update Report